Diabetes and SARS-CoV-2 Infection: The Potential Role of Antidiabetic Therapy in the Evolution of COVID-19

Biagio Pinchera; Nicola Schiano Moriello; Antonio Riccardo Buonomo; Isabella Di Filippo; Anastasia Tanzillo; Giorgio Buzzo; Riccardo Villari; Ivan Gentile; Federico Ii Covid Team

doi:10.3390/microorganisms11010145

Diabetes and SARS-CoV-2 Infection: The Potential Role of Antidiabetic Therapy in the Evolution of COVID-19

Microorganisms. 2023 Jan 6;11(1):145. doi: 10.3390/microorganisms11010145.

Authors

Biagio Pinchera¹, Nicola Schiano Moriello¹, Antonio Riccardo Buonomo¹, Isabella Di Filippo¹, Anastasia Tanzillo¹, Giorgio Buzzo¹, Riccardo Villari¹, Ivan Gentile¹, Federico Ii Covid Team¹

Affiliation

¹ Section of Infectious Diseases, Department of Clinical Medicine and Surgery, University of Naples Federico II, 80131 Naples, Italy.

Abstract

Diabetes mellitus represents one of the most frequent comorbidities among patients with COVID-19, constituting a risk factor for a more severe prognosis than that of non-diabetic patients. However, the pathophysiological mechanism underlying this unfavorable outcome is still not completely clear. The goal of our study was to evaluate the potential role of antidiabetic therapy in the evolution of COVID-19.

Keywords: COVID-19; SARS-CoV-2; diabetes; insulin; mTOR; metformin.

Grants and funding

This research received no grants from any funding campaign, and the authors received no financial support for this study.